-DOCSTART- -X- O
Appropriate -X- _ O
adjuvant -X- _ O
selection -X- _ O
may -X- _ O
be -X- _ O
essential -X- _ O
to -X- _ O
optimize -X- _ O
the -X- _ O
potency -X- _ O
and -X- _ O
to -X- _ O
tailor -X- _ O
the -X- _ O
immune -X- _ O
response -X- _ O
of -X- _ O
subunit -X- _ O
vaccines. -X- _ O
To -X- _ O
induce -X- _ O
protective -X- _ O
responses -X- _ O
against -X- _ O
respiratory -X- _ O
syncytial -X- _ O
virus -X- _ O
( -X- _ O
RSV -X- _ O
) -X- _ O
—a -X- _ O
highly -X- _ O
prevalent -X- _ O
childhood -X- _ O
pathogen -X- _ O
without -X- _ O
a -X- _ O
licensed -X- _ O
vaccine—we -X- _ O
previously -X- _ O
engineered -X- _ O
a -X- _ O
pre-fusion-stabilized -X- _ O
trimeric -X- _ O
RSV -X- _ O
F -X- _ O
( -X- _ O
pre-F -X- _ O
) -X- _ O
“DS-Cav1” -X- _ O
immunogen -X- _ O
, -X- _ O
which -X- _ O
induced -X- _ O
high -X- _ O
titer -X- _ O
RSV-neutralizing -X- _ O
antibodies -X- _ O
, -X- _ O
in -X- _ O
mice -X- _ O
and -X- _ O
non-human -X- _ O
primates -X- _ O
, -X- _ O
when -X- _ O
formulated -X- _ O
with -X- _ O
adjuvants -X- _ O
Poly -X- _ O
( -X- _ O
I -X- _ O
: -X- _ O
C -X- _ O
) -X- _ O
and -X- _ O
Poly -X- _ O
( -X- _ O
IC -X- _ O
: -X- _ O
LC -X- _ O
) -X- _ O
, -X- _ O
respectively. -X- _ O
To -X- _ O
assess -X- _ O
the -X- _ O
impact -X- _ O
of -X- _ O
different -X- _ O
adjuvants -X- _ O
, -X- _ O
here -X- _ O
we -X- _ O
formulated -X- _ O
RSV -X- _ B-Intervention
F -X- _ I-Intervention
DS-Cav1 -X- _ I-Intervention
with -X- _ I-Intervention
multiple -X- _ I-Intervention
adjuvants -X- _ I-Intervention
and -X- _ O
assessed -X- _ O
immune -X- _ O
responses. -X- _ O
Very -X- _ B-Outcome
high -X- _ I-Outcome
RSV-neutralizing -X- _ I-Outcome
antibody -X- _ I-Outcome
responses -X- _ I-Outcome
( -X- _ I-Outcome
19,006 -X- _ I-Outcome
EC -X- _ I-Outcome
( -X- _ I-Outcome
50 -X- _ I-Outcome
) -X- _ I-Outcome
) -X- _ I-Outcome
were -X- _ I-Outcome
observed -X- _ I-Outcome
in -X- _ I-Outcome
naïve -X- _ I-Outcome
mice -X- _ I-Outcome
immunized -X- _ I-Outcome
with -X- _ I-Outcome
2 -X- _ I-Outcome
doses -X- _ I-Outcome
of -X- _ I-Outcome
DS-Cav1 -X- _ I-Outcome
adjuvanted -X- _ I-Outcome
with -X- _ I-Outcome
Sigma -X- _ I-Outcome
adjuvant -X- _ I-Outcome
system -X- _ I-Outcome
( -X- _ I-Outcome
SAS -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
an -X- _ I-Outcome
oil-in-water -X- _ I-Outcome
adjuvant -X- _ I-Outcome
, -X- _ I-Outcome
plus -X- _ I-Outcome
Carbopol -X- _ I-Outcome
; -X- _ I-Outcome
high -X- _ I-Outcome
responses -X- _ I-Outcome
( -X- _ I-Outcome
3658–7108 -X- _ I-Outcome
) -X- _ I-Outcome
were -X- _ I-Outcome
observed -X- _ I-Outcome
with -X- _ I-Outcome
DS-Cav1 -X- _ I-Outcome
adjuvanted -X- _ I-Outcome
with -X- _ I-Outcome
Alum -X- _ I-Outcome
, -X- _ I-Outcome
SAS -X- _ I-Outcome
alone -X- _ I-Outcome
, -X- _ I-Outcome
Adjuplex -X- _ I-Outcome
, -X- _ I-Outcome
Poly -X- _ I-Outcome
( -X- _ I-Outcome
I -X- _ I-Outcome
: -X- _ I-Outcome
C -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
Poly -X- _ I-Outcome
( -X- _ I-Outcome
IC -X- _ I-Outcome
: -X- _ I-Outcome
LC -X- _ I-Outcome
) -X- _ I-Outcome
; -X- _ I-Outcome
and -X- _ I-Outcome
moderate -X- _ I-Outcome
responses -X- _ I-Outcome
( -X- _ I-Outcome
1251–2129 -X- _ I-Outcome
) -X- _ I-Outcome
were -X- _ I-Outcome
observed -X- _ I-Outcome
with -X- _ I-Outcome
DS-Cav1 -X- _ I-Outcome
adjuvanted -X- _ I-Outcome
with -X- _ I-Outcome
the -X- _ I-Outcome
TLR4 -X- _ I-Outcome
agonist -X- _ I-Outcome
MPLA -X- _ I-Outcome
, -X- _ I-Outcome
Alum -X- _ I-Outcome
plus -X- _ I-Outcome
MPLA -X- _ I-Outcome
or -X- _ I-Outcome
AddaVax. -X- _ I-Outcome
In -X- _ I-Outcome
contrast -X- _ I-Outcome
, -X- _ I-Outcome
DS-Cav1 -X- _ I-Outcome
without -X- _ I-Outcome
adjuvant -X- _ I-Outcome
induced -X- _ I-Outcome
low-level -X- _ I-Outcome
responses -X- _ I-Outcome
( -X- _ I-Outcome
6 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
A -X- _ I-Outcome
balanced -X- _ I-Outcome
IgG1 -X- _ I-Outcome
and -X- _ I-Outcome
IgG2a -X- _ I-Outcome
( -X- _ I-Outcome
Th2 -X- _ I-Outcome
/ -X- _ I-Outcome
Th1 -X- _ I-Outcome
) -X- _ I-Outcome
immune -X- _ I-Outcome
response -X- _ I-Outcome
was -X- _ I-Outcome
elicited -X- _ I-Outcome
in -X- _ I-Outcome
most -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
high -X- _ I-Outcome
to -X- _ I-Outcome
very -X- _ I-Outcome
high -X- _ I-Outcome
response -X- _ I-Outcome
groups -X- _ I-Outcome
( -X- _ I-Outcome
all -X- _ I-Outcome
but -X- _ I-Outcome
Alum -X- _ I-Outcome
and -X- _ I-Outcome
Adjuplex -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
We -X- _ O
also -X- _ O
tested -X- _ O
the -X- _ O
immune -X- _ O
response -X- _ O
induced -X- _ O
by -X- _ O
DS-Cav1 -X- _ O
in -X- _ O
elderly -X- _ B-Patient
mice -X- _ I-Patient
with -X- _ O
pre-existing -X- _ O
DS-Cav1 -X- _ O
immunity -X- _ O
; -X- _ O
we -X- _ O
observed -X- _ O
that -X- _ O
DS-Cav1 -X- _ O
adjuvanted -X- _ O
with -X- _ O
SAS -X- _ O
plus -X- _ O
Carbopol -X- _ O
boosted -X- _ O
the -X- _ O
response -X- _ O
2-3-fold -X- _ O
, -X- _ O
whereas -X- _ O
DS-Cav1 -X- _ O
adjuvanted -X- _ O
with -X- _ O
alum -X- _ O
boosted -X- _ O
the -X- _ O
response -X- _ O
5-fold. -X- _ O
Finally -X- _ O
, -X- _ O
we -X- _ O
tested -X- _ O
whether -X- _ O
a -X- _ O
mixture -X- _ O
of -X- _ O
ISA -X- _ O
71 -X- _ O
VG -X- _ O
and -X- _ O
Carbopol -X- _ O
would -X- _ O
enhanced -X- _ O
the -X- _ O
antibody -X- _ O
response -X- _ O
in -X- _ O
DS-Cav1 -X- _ O
immunized -X- _ O
calves. -X- _ O
While -X- _ O
pre-F-stabilized -X- _ O
bovine -X- _ O
RSV -X- _ O
F -X- _ O
induced -X- _ O
very -X- _ O
high -X- _ O
titers -X- _ O
in -X- _ O
mice -X- _ O
when -X- _ O
adjuvanted -X- _ O
with -X- _ O
SAS -X- _ O
plus -X- _ O
Carbopol -X- _ O
, -X- _ O
the -X- _ O
addition -X- _ O
of -X- _ O
Carbopol -X- _ O
to -X- _ O
ISA -X- _ O
71 -X- _ O
VG -X- _ O
did -X- _ O
not -X- _ O
enhance -X- _ O
immune -X- _ O
responses -X- _ O
in -X- _ O
calves. -X- _ O
The -X- _ O
vaccine -X- _ O
response -X- _ O
to -X- _ O
pre-F-stabilized -X- _ O
RSV -X- _ O
F -X- _ O
is -X- _ O
augmented -X- _ O
by -X- _ O
adjuvant -X- _ O
, -X- _ O
but -X- _ O
the -X- _ O
degree -X- _ O
of -X- _ O
adjuvant-induced -X- _ O
enhancement -X- _ O
appears -X- _ O
to -X- _ O
be -X- _ O
both -X- _ O
context-dependent -X- _ O
and -X- _ O
species-specific -X- _ O
. -X- _ O

